There has been growing interest among the public and scientists in dichloroacetate (DCA) as a potential anticancer drug. Credible evidence exists for the antitumor activity of this compound, but high concentrations are needed for significant therapeutic effect. Unfortunately, these high concentrations produce detrimental side effects involving the nervous system, thereby precluding its use for cancer treatment. The mechanistic basis of the compound's antitumor activity is its ability to activate the pyruvate dehydrogenase complex through inhibition of pyruvate dehydrogenase kinase. As the compound inhibits the kinase at micromolar concentrations, it is not known why therapeutically prohibitive high doses are needed for suppression of tumor growth. We hypothesized that lack of effective mechanisms for the entry of DCA into tumor cells may underlie this phenomenon. Here we show that SLC5A8 transports DCA very effectively with high affinity. This transporter is expressed in normal cells, but expression is silenced in tumor cells by epigenetic mechanisms. The lack of the transporter makes tumor cells resistant to the antitumor activity of DCA. However, if the transporter is expressed in tumor cells ectopically, the cells become sensitive to the drug at low concentrations. This is evident in breast cancer cells, colon cancer cells and prostate cancer cells. Normal cells, which constitutively express the transporter, are however not affected by the compound, indicating tumor cell-selective therapeutic activity. The mechanism of the compound's antitumor activity still remains its ability to inhibit pyruvate dehydrogenase kinase and force mitochondrial oxidation of pyruvate. As silencing of SLC5A8 in tumors involves DNA methylation and its expression can be induced by treatment with DNA methylation inhibitors, our findings suggest that combining DCA with a DNA methylation inhibitor would offer a means to reduce the doses of DCA to avoid detrimental effects associated with high doses but without compromising antitumor activity.
Introduction
Dichloroacetate (DCA) is currently used for the treatment of congenital lactic acidosis (Stacpoole et al., 2003 (Stacpoole et al., , 2008 . The therapeutic efficacy of this drug is attributable to its ability to activate the pyruvate dehydrogenase complex (PDC) in the mitochondrial matrix. However, the enzyme complex is not the direct target for the drug. DCA is an inhibitor of pyruvate dehydrogenase kinase (PDK), which phosphorylates the E1a subunit of PDC and inactivates the complex (Stacpoole et al., 2003 (Stacpoole et al., , 2008 . By inhibiting PDK, DCA prevents the phosphorylation of E1a and thus maintains PDC in active form. The drug-induced activation of PDC facilitates mitochondrial metabolism of pyruvate. As cytosolic pyruvate can either be transported into mitochondria and metabolized or be converted into lactate in the cytoplasm by lactate dehydrogenase, activation of PDC by DCA and the resultant metabolism of pyruvate within mitochondria shifts the equilibrium between pyruvate and lactate toward pyruvate. This promotes the conversion of lactate into pyruvate, thus reducing lactate levels.
In recent years there has been considerable interest in DCA as a potential anticancer drug (Michelakis et al., 2008) . The notion that this drug may have the ability to kill tumor cells has a rational basis. Tumor cells derive most of their energy from aerobic glycolysis rather than mitochondrial oxidation. This metabolic shift in tumor cells was first recognized by Warburg (1956) and has thus become known as the Warburg effect (Gatenby and Gillies, 2004; Kim and Dang, 2006; Brahimi-Horn et al., 2007; Chen et al., 2007; Ganapathy et al., 2009; Vander Heiden et al., 2009; Mathupala et al., 2010) . Given that aerobic glycolysis, which converts glucose into lactate, generates only two ATP whereas mitochondrial oxidation of glycolysis-derived pyruvate generates 30 ATP molecules, it seems puzzling that tumor cells prefer the less efficient metabolic pathway to obtain energy. Tumor cells, however, do not suffer from ATP deficiency; in fact they generate more energy than normal cells to support their enhanced growth and proliferation. This is achieved by activation of glycolysis by several fold. It is true that mitochondrial oxidation generates more ATP than cytoplasmic glycolysis, but at the same time mitochondrial oxidation produces reactive oxygen species, which could prove to be detrimental to cells. Apparently, tumor cells recognize this negative aspect of mitochondrial oxidation and therefore choose glycolysis as the primary source for ATP. Glycolysis does not require oxygen and does not generate reactive oxygen species. Additionally, with generation of energy predominantly through glycolysis, tumor cells can proliferate in anerobic conditions, which often exist in solid tumors. However, suppression of mitochondrial function in tumors is reversible. Interestingly, one of the mechanisms by which tumor cells suppress mitochondrial oxidation is by inducing PDK, thereby inactivating PDC (Semenza, 2010) . Therefore, oxidation of pyruvate in mitochondria can be induced in tumor cells by reversing the cancer-associated suppression of PDC activity. DCA does exactly that, by inhibiting PDK. Despite this rational basis for DCA as a potential anticancer drug, there is considerable controversy in the literature regarding the clinical utility of this compound for cancer treatment in humans. Even though the study by Bonnet et al. (2007) demonstrated the antitumor efficacy of DCA in vitro and in vivo in animals, a recent study by Stockwin et al. (2010) has shown that very high concentrations of DCA are needed to induce cell death in tumor cells and that at these concentrations the compound has no tumor cell selectivity.
DCA is ionized and cannot pass through the plasma membrane by diffusion. This raises the question as to how this compound gets into cells and gains access to PDK within the mitochondrial matrix. To the best of our knowledge, there has been only a single report on the transport of DCA into mammalian cells, which has shown that monocarboxylate transporters in hepatocytes and Ehrlich Lettre tumor cells mediate the cellular entry of this compound (Jackson and Halestrap, 1996) . As the monocarboxylate transporters are electroneutral, most cells, including tumor cells, which express these transporters, may not have the ability to concentrate this drug. Recently we and others have identified a new transporter for monocarboxylates, which has substrate selectivity similar to that of the monocarboxylate transporters, but is Na þ -coupled and electrogenic (Coady et al., 2004; Miyauchi et al., 2004) . This transporter, known as sodium-coupled monocarboxylate transporter (SMCT1) or solute carrier family-5 member-8 (SLC5A8) according to the Human Genome Organization nomenclature, has the ability to concentrate its substrates against a concentration gradient because of the involvement of transmembrane Na þ gradient and membrane potential as driving forces. SLC5A8 transports acetate, propionate, butyrate, lactate, pyruvate, 3-bromopyruvate, nicotinate, b-hydroxybutyrate and pyroglutamate Miyauchi et al., 2004 Miyauchi et al., , 2010 Martin et al., 2006; Thangaraju et al., 2006 Thangaraju et al., , 2008 Thangaraju et al., , 2009a . We wondered whether this highly energy-coupled transporter would accept DCA as a substrate. This issue is directly relevant to the antitumor activity of this drug because tumor cells silence this transporter by epigenetic mechanisms (Ganapathy et al., , 2008 (Ganapathy et al., , 2009 Gupta et al., 2006) . Therefore, we undertook this study to address two questions: (a) Does SLC5A8 transport DCA? (b) Does the antitumor activity of the drug depend on the expression of the transporter in tumor cells? The results of the study show that SLC5A8 is obligatory for the antitumor activity of DCA.
Results
SLC5A8 transports DCA in an Na þ -coupled manner The transport of acetate and its chloro derivatives by human SLC5A8 was studied using the Xenopus laevis oocyte expression system. The human transporter was expressed heterologously in oocytes by injection of SLC5A8 cRNA. The transport function was monitored electrophysiologically by the two-microelectrode voltage-clamp technique. SLC5A8 functions as an Na þcoupled transporter for monocarboxylates with an Na þ :monocarboxylate stoichiometry of 2:1. The transport process is therefore electrogenic, associated with the transfer of one net positive charge into cells per transport cycle. The resultant depolarization of the membrane can be monitored as an inward current under voltage-clamp conditions. As can be seen in Figure 1a , exposure of SLC5A8-expressing oocytes to acetate (1 mM) induced inward currents when monitored in the presence of Na þ in the perfusion medium (129±9 nA; n ¼ 3 oocytes). However, these currents were not observed in the absence of Na þ . These data show that SLC5A8 mediates acetate transport in an Na þ -coupled manner. Saturation kinetics showed that the Michaelis constant (K t ) for the transport process was 1.6 ± 0.1 mM. After establishing the functional activity of the cloned human SLC5A8 using acetate as a positive control, we examined the transport of DCA. Exposure of SLC5A8expressing oocytes to DCA (0.25 mM) induced marked inward currents in the presence of Na þ (153±28 nA; n ¼ 5 oocytes) (Figure 2a ). Such currents were not observed in the absence of Na þ . The transport process was saturable with a K t of 36±7 mM (Figure 2b) . Thus, the affinity of DCA for the transporter is B45-fold higher than that of acetate. The DCA (0.25 mM)-induced currents increased with increase in the concentration of Na þ in the perfusion medium ( Figure 2c ). The relationship was sigmoidal, indicating involvement of more than one Na þ in the activation process. Analysis of the data according to Hill equation yielded a value of 2.1±0.2 for the Hill coefficient. These data show that the Na þ :DCA stoichiometry for the transport process is 2:1.
We also used an alternative method to assess the transport of DCA by SLC5A8. This method used [ 14 C]nicotinate as substrate for SLC5A8. Water-injected oocytes did not express the transporter and hence were used as controls. The uptake of [ 14 C]nicotinate (50 mM) was 60-fold higher in SLC5A8-expressing oocytes than in water-injected oocytes ( Figure 2d ). The SLC5A8specific uptake of nicotinate was inhibited 480% in the presence of acetate (0.25 mM) or DCA (0.25 mM), indicating that acetate and DCA compete with nicotinate for uptake by SLC5A8.
These findings showed that DCA is a high-affinity substrate for human SLC5A8. We then studied the transport of monochloroacetate and trichloroacetate for comparison ( Figure 3 ). Both compounds were transported by SLC5A8 in a Na þ -coupled and saturable manner. The K t was 177 ± 16 mM for monochloroacetate and 134±11 mM for trichloroacetate.
DCA-induced apoptosis in cancer cells requires SLC5A8
Even though several studies have shown that DCA induces apoptosis in a variety of cancer cell lines (Bonnet et al., 2007; Cao et al., 2008; Wong et al., 2008) , a recent investigation was not able to confirm these findings (Stockwin et al., 2010) . The studies by Bonnet et al. (2007) showed that DCA at a concentration of 0.5 mM was able to induce metabolic changes specifically in cancer cells and not in normal cells. These changes included depolarization of the mitochondrial membrane, suppression of glycolysis, enhancement of mitochondrial oxidation, production of reactive oxygen species, induction of the plasma membrane potassium channel Kv1.5 and release of pro-apoptotic factors from mitochondria. Wong et al. (2008) subsequently showed that DCA caused apoptosis in endometrial cancer cells, and Cao et al. (2008) showed that the compound sensitized prostate cancer cells to radiation. By contrast, the studies by Stockwin et al. (2010) showed that even though DCA was able to induce mitochondrial depolarization and reactive oxygen species generation, these changes occurred in cancer cells as well as in normal cells. Furthermore, a very high concentration of the compound (X25 mM) was required to induce apoptosis. Based on the findings of our present study that SLC5A8 mediates energy-coupled active entry of DCA into cells, and the fact that cancer cells silence the transporter, we wondered whether absence of the transporter in cancer cells was the reason for the lack of detectable apoptosis at low concentrations of the compound as observed by Stockwin et al. (2010) . We addressed this question using three different human colon cancer cell lines (HCT116, SW620 and HT29). These three cell lines do not express SLC5A8 . We also confirmed the absence of SLC5A8 expression in human colon and breast cancer cell lines at protein level (Figures 4a and b ). We expressed SLC5A8 in HCT116, SW620 and HT29 cell lines by transient transfection of a mammalian expression construct and confirmed the expression by reverse transcription-PCR (RT-PCR) and western blot analysis ( Figure 4c ). Cells transfected with empty vector served as controls. We then exposed control and SLC5A8expressing cells to DCA (1 mM) for 48 h and monitored apoptosis (Figures 4d-f ). The results were interesting: in control cells, which did not express the transporter, DCA did not have any significant effect. However, under identical conditions, SLC5A8-expressing cells underwent apoptosis to a marked extent. This phenomenon was seen in all three colon cancer cell lines. Monochloroacetate also behaved similar to DCA in HCT116 and SW620 cells though not in HT29 cells where the ability of monochloroacetate to induce apoptosis was significantly lower than that of DCA. Acetate and trichloroacetate were without any noticeable effect. We used butyrate as a positive control in these experiments based on our previous report that induction of apoptosis by butyrate in colon cancer cell lines is obligatorily dependent on the expression of SLC5A8 .
We then wanted to determine whether DCA-induced apoptosis shows tumor cell selectivity and also whether the effect is seen in cancer cell lines of tissue origin other than colon. For this, we selected CCD841 and MCF10A as the representative of normal cell lines (CCD841, colon; MCF10A, mammary epithelium) and four human cancer cell lines: MCF7 (an estrogen receptorpositive breast cancer cell line), MB231 (an estrogen receptor-negative breast cancer cell line), DU145 (an androgen-insensitive prostate cancer cell line) and LNCaP (an androgen-sensitive prostate cancer cell line). As reported previously (Thangaraju et al., 2006 , the normal cell lines CCD841 and MCF10A expressed detectable levels of SLC5A8, at both mRNA and protein levels (Figure 5a ). By contrast, none of the four cancer cell lines examined here expressed the transporter. The expression became evident in cancer cell lines upon transient transfection of a mammalian expression construct. In normal cells, the expression levels increased upon transfection. Using these cell lines, we compared the ability of DCA to induce apoptosis between normal and cancer cell lines (Figure 5b ). We found no significant difference in apoptosis in normal cell lines with and without treatment with DCA (1 mM). The increased levels of SLC5A8 expression also did not have any effect on the extent of apoptosis. By contrast, DCA was able to induce marked apoptosis in the four cancer cell lines, but only if the cells expressed the transporter. Without the expression of the transporter, the cancer cell lines did not undergo apoptosis upon treatment with DCA. These results show that DCA is able to cause apoptosis even at concentrations as low as 1 mM in a cancer cell-selective manner, but only if SLC5A8 is expressed. These observations were also confirmed with lentivirus-mediated stable expression of SLC5A8 (doxycycline-inducible) in two breast cancer cell lines, MCF7 and MB231 (Figures 5c and d ). It has been well established that silencing of SLC5A8 is associated with DNA methylation and that treatment of cancer cells with DNA-demethylating agents reactives SLC5A8 expression. Therefore, we treated normal and cancer cell lines with 5-aza-2-deoxycytidine (5-Azadc), a DNA-demethylating agent, and re-activation of SLC5A8 was confirmed by immunoblotting analysis (Figure 5e ). 5-Azadc treatment did not alter SLC5A8 protein expression in normal colon and mammary epithelial cells, whereas it re-activated SLC5A8 expression in all cancer cell lines. Furthermore, treatment of these cells with 5-Azadc itself induced significant apoptosis; however, treatment of these cells with DCA (1 mM) dramatically enhanced the 5-Azadc-induced apoptosis (Figure 5f ).
Effect of DCA on intracellular levels of pyruvate
What is the mechanism responsible for the induction of apoptosis by SLC5A8/ DCA in cancer cells? SLC5A8 is an active transporter for DCA with a K t of 36 ± 7 mM. Therefore, the compound will be concentrated in cancer cells if the transporter is expressed. This would explain the obligatory requirement for SLC5A8 for low concentrations of DCA to induce apoptosis in these cells. If the transporter is not expressed, cells may not accumulate the compound to levels sufficient enough to cause apoptosis. Once accumulated inside the cancer cells, how does DCA act to induce apoptosis? The only known mechanism of action of DCA is its ability to activate PDC through inhibition of PDK (Stacpoole al., 1998, 2003, 2008) . This would result in stimulation of mitochondrial oxidation, generation of reactive oxygen species, depolarization of mitochondrial membrane potential and induction of apoptosis. Activation of PDC by DCA in intact cells would decrease intracellular levels of pyruvate. Based on this, we hypothesized that DCA would decrease pyruvate levels in cancer cells and that the effect would be obligatorily dependent on SLC5A8 expression. We tested this hypothesis in three different cancer cell lines (HT29, SW620 and HCT116) with and without exogenous expression of SLC5A8 ( Figure 6 ). The expression of the transporter by itself did not have any effect on the intracellular levels of pyruvate. DCA was able to decrease the levels of pyruvate to a significant extent in all three cancer cell lines, but only when the transporter was expressed. Interestingly, monochloroacetate also had a similar effect, again only in the presence of SLC5A8; by contrast, trichloroacetate and acetate were not able to affect pyruvate levels.
Until now the only mechanism by which SLC5A8 functions as a tumor suppressor was through its ability to concentrate inside cells butyrate and pyruvate, which are inhibitors of histone deacetylases (HDACs). We have shown in the present study that DCA also induces apoptosis in cancer cells and that the effect is dependent on the expression of SLC5A8. These findings are similar to those with butyrate and pyruvate. Therefore, we wondered whether there is any involvement of inhibition of HDACs in DCA-induced apoptosis in cancer cells. This seemed unlikely, however, because acetate is not an inhibitor of HDACs (Thangaraju et al., 2006) . However, we could not rule out the possibility that DCA may function as an inhibitor of HDACs. Therefore, we examined the influence of acetate, monochloroacetate, DCA and butyrate on the activity of HDACs. First, we used lysates of SW620 cells as the source of HDACs (Figure 7a ). Butyrate was used as positive control in these experiments. As expected, butyrate inhibited the activity of HDACs. Under identical conditions, DCA was at least 100-fold less potent compared with butyrate in inhibiting HDACs. We then used recombinant human HDAC isoforms to determine whether specific isoforms of the enzyme could be inhibited by DCA. Our previous studies have shown that butyrate is a specific inhibitor of the HDAC isoforms HDAC1 and HDAC3 (Thangaraju et al., 2009b) . In the present study, we observed the same with butyrate ( Figure 7b ). DCA also inhibited the isoforms HDAC1, HDAC2 and HDAC5 to a significant extent, but the potency was very low (B20% inhibition at a concentration of 1 mM) ( Figure 7c ). Acetate (Figure 7d ) and monochloroacetate (Figure 7e ) did not have any effect on any of the isoforms examined in the study.
Discussion
Since the publication of the paper in Cancer Cell by Bonnet et al. (2007) that showed DCA promotes apoptosis in cancer cell lines in vitro and inhibits cancer growth in mouse xenografts in vivo, there has been a steady increase in public interest in the potential utility of this compound as an anticancer drug. DCA has been in use as a drug for treatment of congenital lactic acidosis and therefore details of the drug's pharmacokinetics and toxicity profile have been worked out (Stacpoole et al., 1998) . The recent findings that the drug may also be useful in cancer treatment have prompted many cancer patients to use this unapproved drug without their physicians' recommendation (Pearson, 2007) . Interestingly, there have been no controlled clinical trials to document the therapeutic efficacy of dichloroacetate as an anticancer drug. As the structure of DCA cannot be patented, apparently pharmaceutical companies were not interested in developing the drug for cancer therapy through clinical trials, thus prompting the principal investigator of the original publication in Cancer Cell to raise funds for his own small clinical trials (Pearson, 2007) . The results of the clinical trial have been published recently (Michelakis et al., 2010) , which has shown that the drug is effective in patients with glioblastoma. Unfortunately, even though the drug was effective in vivo in the treatment of glioblastoma, high concentrations of the drug had to be used for therapeutic efficacy, which resulted in peripheral neuropathy. This was the only undesirable side effect that was limiting the use of higher dosage of the drug for greater therapeutic efficacy. There was no evidence of hematologic, hepatic, renal or cardiac toxicity. Several studies have documented neurological complications with high doses of DCA in animals and in humans (Calcutt et al., 2009; Weimer and Sachdev, 2009; Brandsma et al., 2010) . The neurological complications occur only at very high doses of DCA: 12.5 mg/kg/day for 3 months (Bonnet et al., 2007) or 15 mg/kg/day for 4 weeks (Brandsma et al., 2010) . The need for high doses of DCA to be therapeutically effective in vivo agrees with most of the recently published in vitro data that show that concentrations 10 mM or higher are necessary to cause apoptosis in cancer cell lines (Heshe et al., 2010; Madhok et al., 2010; Stockwin et al., 2010; Sun et al., 2010; Xiao et al., 2010) .
There is convincing evidence that DCA has the ability to reverse the metabolic phenotype of cancer cells and promote their death, but the antitumor effect is seen only at very high concentrations both in vitro and in vivo. As neurological toxicity occurs at these therapeutically effective concentrations, the utility of the compound as an anticancer drug is limited in humans. Interestingly, the only molecular target for the antitumor activity of DCA is PDK, which is inhibited by the compound at micromolar concentrations (inhibition constant, 50-100 mM) Whitehouse et al., 1974) . Why is it then that high millimolar concentrations of DCA are needed in vitro to kill cancer cells? This question has to be answered in order to exploit the potential of this compound as an anticancer drug. Our present studies provide a satisfactory answer to this important question. Cancer cells do not express any transport system that can effectively transfer the compound from the extracellular medium to its intracellular target. Monocarboxylate transporters that are expressed in cancer cells transport DCA with a K t of 0.6 mM (Jackson and Halestrap, 1996) . This is a low-affinity transport process. Furthermore, monocarboxylate transporters are not highly concentrative. In addition, tumor cells generate large quantities of lactate, which is also a substrate for monocarboxylate transporters with an affinity comparable to that of DCA, thus causing competition for the transport process. These studies show that SLC5A8 transports DCA with an affinity that is considerably greater than that of monocarboxylate transporters (K t : 36mM versus 600 mM). Even more important is the fact that SLC5A8 is much more effective than the monocarboxylate transporters in transporting DCA because of the energization of the former by a transmembrane electrochemical Na þ gradient. It is interesting to note that the affinity for the transporter changes drastically by chlorination of the second carbon in acetate (K t : 1572±101 mM for acetate; 177±16 mM for monochloroacetate; 36±7 mM for DCA; 134 ± 11 mM for trichloroacetate). Our findings lead us to conclude that tumor cells are resistant to DCA-induced apoptosis because these cells do not possess effective transport systems for the drug. This is It is also possible that the cell death observed in tumor cells at these high concentrations is not because of activation of PDC because similar effects are also seen in normal cells (Stockwin et al., 2010) .
In the present study, we have shown that, if SLC5A8 is expressed in tumor cells, DCA induces cell death at a relatively lower concentration (1 mM) in a tumor cellselective manner. Under identical conditions, normal cells (CCD841 and MCF10A) are not affected. The resistance of normal cells to DCA is not caused by the absence of a transport system for the drug. Normal cells express SLC5A8 constitutively, and we have shown that the cells do not undergo apoptosis with or without additional expression of the transporter. This confirms the tumor cell-specific effect of DCA. Our studies have also shown that the efficacy of DCA as an inducer of apoptosis is seen not only with colon cancer cell lines but also with breast cancer cell lines and prostate cancer cell lines. The mechanism of DCA-induced cell death in cancer cells is principally because of activation of mitochondrial oxidation of pyruvate. This is supported by the findings that intracellular levels of pyruvate in cancer cells decrease in response to treatment with DCA in an SLC5A8-dependent manner, suggesting that concentrative entry of the drug into cancer cells mediated by the exogenously expressed SLC5A8 is responsible for this effect. DCA does not inhibit HDACs, which precludes inhibition of HDACs as a potential mechanism of apoptosis in tumor cells induced by the compound.
The findings that DCA induces cell death selectively in tumor cells at low concentrations but only if SLC5A8 is expressed have clinical and therapeutic significance. The ability of DCA to activate PDC by inhibition of PDK in cancer cells provides a mechanistically rational basis for the antitumor activity of the compound. But cancer cells are resistant to the drug because of the absence of an effective transporter for the drug, necessitating requirement of high concentrations of the compound to induce cell death, which unfortunately causes detrimental side effects such as neuropathy. We have shown in the present study that SLC5A8 serves as an active transporter for DCA. However, as the expression of the transporter is silenced in tumor cells, how can the present findings be relevant to the potential therapeutic use of the drug? The silencing of SLC5A8 in cancer cells occurs by epigenetic mechanisms involving DNA methylation; treatment of cancer cells with 5 0 -azacytidine, an inhibitor of DNA methylation, reactivates the expression of the gene (Li et al., 2003; Ueno et al., 2004; Hong et al., 2005; Porra et al., 2005; Thangaraju et al., 2006; Park et al., 2007 Park et al., , 2008 . DNA methylation has a critical role in silencing tumor suppressor genes in a variety of cancers, and DNA methylation inhibitors hold promise as anticancer drugs (Baylin, 2005) . Two compounds with DNA methylation inhibition activity are in clinical use for treatment of hematologic malignancies. These are 5 0 -aza-2 0 -deoxycytidine, also known as decitabine (trade name, Dacogen) and 5 0 -azacytidine (trade name, Vidaza). In vitro studies have shown that treatment of a variety of cancer cell lines with these compounds re-activates the expression of SLC5A8. We speculate that the same phenomenon would also occur in vivo. Therefore, a combination of a DNA methylation inhibitor and DCA is likely to be effective for treatment of cancer because the DNA methylation inhibitor would induce the expression of SLC5A8 in tumors, which would then effectively transport DCA into tumor cells to elicit its antitumor activity. This mode of treatment would considerably reduce the concentration of DCA necessary for in vivo efficacy as an anticancer agent, thus potentially providing tumor selectivity and also avoiding detrimental side effects such as neuropathy. The findings of the present study provide a rational basis for such a combination therapy.
Materials and methods

Materials
[ 14 C]Nicotinate was purchased from American Radiolabeled Chemicals (St Louis, MO, USA). Acetate and its chloro derivatives were obtained from Sigma (St Louis, MO, USA).
SLC5A8 was originally cloned from human intestine .
X. laevis oocyte expression system
Capped cRNA from human SLC5A8 cDNA (cloned in pGH19, an X. laevis oocyte expression vector) was synthesized using the mMESSAGE-mMACHINE kit (Ambion, Austin, TX, USA). Mature oocytes from X. laevis were isolated by treatment with collagenase-A (1.6 mg/ml), manually defolliculated and maintained at 18 1C in modified Barth's medium supplemented with 25 mg/ml gentamicin. Oocytes were injected with 50 ng of cRNA. Water-injected oocytes served as controls. Electrophysiological studies were performed by the two-microelectrode voltage-clamp method. Oocytes were perifused with an NaCl-containing buffer (100 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 mM Hepes (pH 7.5)) followed by the same buffer containing acetate or its chloro derivatives. The membrane potential was clamped at À50 mV. The differences between the steady-state currents measured in the presence and absence of substrates were considered as the substrate-induced currents. In the analysis of the saturation kinetics of substrate-induced currents, the kinetic parameter K t (that is, substrate concentration necessary for induction of half-maximal current) was calculated by fitting the Michaelis-Menten equation to the values of the substrate-induced currents. The Na þ -activation kinetics of substrate-induced currents was analyzed by measuring the substrate-specific currents in the presence of increasing concentrations of Na þ . The data for the Na þ -dependent currents were analyzed according to the Hill equation to determine the Hill coefficient (the number of Na þ ions involved in the activation process). As expression levels varied significantly among oocytes, kinetic analyses were performed by normalizing the expression levels. This was done by taking the maximally induced SLC5A8-specific current in each kinetic experiment in individual oocytes as 1. Each experiment was repeated with 3 or 4 different oocytes. The activity of the heterologously expressed SLC5A8 in oocytes was also monitored by [ 14 C]nicotinate uptake. The concentration of nicotinate in these experiments was 50 mM and the time of incubation was 1 h.
The protocol for the use of frogs in these experiments was approved by the Institutional Animal Care and Use Committee.
Ectopic expression of SLC5A8 in cultured cell lines
Cells were seeded in 35-mm culture dishes and cultured in the absence of pyruvate. Cells were transfected with pcDNA or human SLC5A8 cDNA using Fugene-6 and Opti-MEM. pEGFP-N1 was used for co-transfection to determine transfection efficiency. After 24 h, cells were treated with or without acetate or its chloro derivatives (1 mM) for 24 h. For fluorescence-activated cell sorting (FACS) analysis, cells were fixed in 50% ethanol, treated with 0.1% sodium citrate, 1 mg/ ml RNase-A and 50 mg/ml propidium iodide, and then subjected to fluorescence-activated cell sorting (FACS; FACS Caliber; Becton Dickinson, Orange City, FL, USA) analysis.
Generation of SLC5A8-expressing stable cell lines
We generated SLC5A8-expressing stable clones in two cell lines, MCF7 and MDA-MB231, to conditionally express SLC5A8 by placing SLC5A8 cDNA under the control of a Tet-dependent promoter (Tet-On Advanced; Clontech, Mountain View, CA, USA). The system contains two elements, the regulator vector (pLVX-Tet-On Advanced) and the response vector (pLVX-Tight-Puro). Briefly, recombinant lentivirus was produced by co-transfecting 293FT cells with the regulator vector (pLVX-Tet-On Advanced) and three other helper vectors, pLP-1, pLP-2 and pVSVG (Invitrogen, Carlsbad, CA, USA) using the Lipofectamine-2000 transfection reagent. Lentiviral supernatant was harvested 72 h after transfection and filtered through a 0.45-mm membrane. MCF7 and MDA-MB231 cells were infected for 24 h with lentivirus in medium containing 8 mg/ml polybrene and cultured for an additional 48 h. Cells were selected with G418 (2 mg/ml) and expression of rTetR protein was checked by western blotting. SLC5A8 was sub-cloned into pLVX-Tight-Puro and SLC5A8 pLVX-Tight-Puro was transduced into MCF7 and MDA-MB231 cells expressing the rTetR protein following the same procedure described above. The cells were selected with 2 mg/ml puromycin and maintained in medium containing Tet-free fetal bovine serum, 0.25 mg/ml puromycin and 250 mg/ml G418. The induction of SLC5A8 mRNA on addition of doxycycline was confirmed by RT-PCR.
Re-activation of SLC5A8 expression by DNA-demethylating agent Cells were seeded in 10-cm dishes at very low density (0.5 Â 10 6 cells per dish) and cultured in respective medium without sodium pyruvate. After 24 h, cells were treated with 5 0 -Azadc (2 mg/ml) for 72 h. The medium was replaced with fresh medium containing 5 0 -Azadc for every 24 h. Following treatment with 5 0 -Azadc, cells were treated with DCA (1 mM) for 48 h. After the treatment cells were harvested and processed for protein extraction as well as for FACS analysis.
Reverse transcription-PCR RNA prepared from normal and cancer cell lines was used for semi-quantitative reverse transcription-PCR (RT-PCR). RNA (2 mg) was reverse-transcribed into cDNA using the GeneAmp PCR system (Applied Biosystem, Foster City, CA, USA). The PCR primers for specific genes were designed based on the nucleotide sequences available in GenBank. RT-PCR was repeated twice with each RNA sample. Glyceraldehyde-3-phosphate dehydrogenase was used as the internal control.
Western blot analysis
Fifty micrograms of protein were fractionated by sodium dodecyl sulfate-PAGE and the fractionated proteins were transferred onto a nitrocellulose membrane (Whatman GmbH). Membranes were blocked with 5% non-fat dry milk and then exposed to an anti-SLC5A8 primary antibody (Aviva System Biology, San Diego, CA, USA) at 4 1C overnight, followed by treatment with appropriate secondary antibodies. Proteins were visualized using the ECL SuperSignal Western System (Thermo Scientific, Rockford, IL, USA).
Analysis of apoptosis
Cells were fixed in 50% ethanol, treated with 0.1% sodium citrate, 1 mg/ml RNase-A and 50 mg/ml propidium iodide, and subjected to FACS (Becton Dickinson) analysis.
Measurement of HDAC activity
A commercially available kit (Biovision, Mountain View, CA, USA) was used to determine HDAC activity. When the cell lysate of the colon cancer cell line SW620 was used as the source of HDAC activity, 100 mg of protein in the lysate was added to the enzyme assay in the presence or absence of acetate or its chloro derivatives (1 mM). The activity of recombinant human HDAC isoforms was also measured using the same kit. The recombinant HDAC isoforms were purchased from Cayman Chemical Company (Ann Arbor, MI, USA).
Measurement of intracellular levels of pyruvate
Cells were seeded in 35-mm culture dishes and cultured in the absence of pyruvate. Cells were transfected with pcDNA or human SLC5A8 cDNA using Fugene-6 and Opti-MEM. After 24 h cells were treated with or without acetate or its chloro derivatives (1 mM) for 24 h. Cell lysates were then used for measurement of pyruvate using a commercially available kit (Biovision).
